Early versus periprocedural administration of abciximab for primary angioplasty:a pooled analysis of 6 studies

Gödicke, Jochen, Flather, Marcus, Noc, Marko, Gyöngyösi, Mariann, Arntz, Hans-Richard, Grip, Lars, Gabriel, Henrique Mesquita, Huber, Kurt, Nugara, Fiona, Schröder, Joachim, Svensson, Leif, Wang, Duolao, Zorman, Simona and Montalescot, Gilles (2005) Early versus periprocedural administration of abciximab for primary angioplasty:a pooled analysis of 6 studies. American Heart Journal, 150 (5). p. 1015. ISSN 0002-8703

Full text not available from this repository. (Request a copy)

Abstract

The 2004 ACC/AHA guidelines on ST-elevation myocardial infarction state that it is reasonable to start treatment with abciximab as early as possible before primary percutaneous coronary intervention (PCI). We investigated the potential benefit of early use of abciximab by pooling data from all the available studies.

Item Type: Article
Uncontrolled Keywords: angioplasty, balloon, coronary,antibodies, monoclonal,female,humans,immunoglobulin fab fragments,male,middle aged,time factors
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:16
Last Modified: 24 Oct 2022 05:37
URI: https://ueaeprints.uea.ac.uk/id/eprint/46282
DOI: 10.1016/j.ahj.2005.07.026

Actions (login required)

View Item View Item